The deal would give GSK the rights to develop the drug for HRD-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

HHS Secretary Robert F. Kennedy Jr. said he will work with Attorney General Pam Bondi to reform the National Vaccine Injury ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion.

GSK (NYSE:GSK) announced on Thursday that EU regulators approved two combination therapies involving its antibody drug ...

Pfizer, GlaxoSmithKline give timeline for IPO of joint venture. Automation in action: Inside Priority Health’s operational overhaul. Recommended Live Webinar on Jul 15, 2025 1:00 PM - 2:00 PM CDT.

Late last week, GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC filed suit in the District of Delaware alleging that Pfizer, Pharmacia & Upjohn, BioNtech SE, BioNtech Manufacturing GMBH ...

Glaxo (GSK) and Pfizer agree to merge their consumer healthcare units into a new joint venture (JV) with almost $13 billion in annual sales. Glaxo will eventually spin-off the joint venture.

GlaxoSmithKline and Pfizer are merging their consumer health care divisions, creating a business with combined sales of 9.8 billion pounds ($12.7B) ...

GlaxoSmithKline and Pfizer <PFE.N>, two leading developers of AIDS drugs, are merging their HIV operations into a new company that will hold nearly a fifth of the market for treatments against the ...

LONDON (AP) — Drugmakers GlaxoSmithKline and Pfizer are merging their healthcare divisions, creating a business with combined sales of 9.8 billion pounds ($12.7 billion). British-based Glaxo ...